EMPHASYS Femoral Stems

K233233 · Depuy Ireland UC · LZO · Oct 11, 2023 · Orthopedic

Device Facts

• Record ID: K233233
• Device Name: EMPHASYS Femoral Stems
• Applicant: Depuy Ireland UC
• Product Code: LZO · Orthopedic
• Decision Date: Oct 11, 2023
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3353
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

EMPHASYS Femoral Stems are intended for use in total and partial hip arthroplasty. The stems are intended only for uncemented use. Total hip arthroplasty is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. Partial hip arthroplasty (hip hemiarthroplasty) is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of a satisfactory natural acetabulum and sufficient femoral bone to seat and support the femoral stem. EMPHASYS Femoral Stems are intended for single use only.

Device Story

EMPHASYS Femoral Stems are orthopedic implants for total or partial hip arthroplasty. Stems are manufactured from titanium alloy (ASTM F620-20) with plasma-sprayed hydroxyapatite (HA) coating (ASTM F1185-14, ISO 13779-6). Available in standard/high offsets and collared/collarless configurations. Intended for uncemented, single-use implantation. Device replaces damaged hip joint articulation to restore mobility and reduce pain. Used by orthopedic surgeons in clinical settings. This submission extends the validated shelf life from 5 to 10 years based on packaging and HA coating stability testing.

Clinical Evidence

No clinical tests were conducted. Substantial equivalence is supported by non-clinical bench testing, including packaging shelf-life validation and HA coating characterization per ISO 13779-3, ASTM F1854, and ASTM E2109.

Technological Characteristics

Titanium alloy (Ti6Al4V) femoral stems with plasma-sprayed HA coating. Materials conform to ASTM F620-20 (titanium) and ASTM F1185-14/ISO 13779-6 (HA). Uncemented fixation. Sterilized via Gamma radiation. Shelf life: 10 years.

Indications for Use

Indicated for total or partial hip arthroplasty in patients with osteoarthritis, traumatic/rheumatoid arthritis, congenital hip dysplasia, avascular necrosis, acute femoral head/neck fractures, failed previous hip surgery, ankylosis, or non-union of femoral neck fractures. Requires sufficient sound bone for component seating. Cementless use only.

Regulatory Classification

Identification

A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.

Predicate Devices

• EMPHASYS Femoral Stems (K211657)
• DePuy CORAIL AMT Hip Prosthesis (K203167)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo for the U.S. Food & Drug Administration (FDA). The logo consists of two parts: a symbol on the left and the FDA name on the right. The symbol is a stylized representation of a human figure, while the FDA name is written in blue and includes the words "U.S. Food & Drug Administration".

October 11, 2023

DePuy Ireland UC Sarah Matamisa Regulatory Affairs Specialist Loughbeg, Ringaskiddy Co. Cork, Ireland

Re: K233233

Trade/Device Name: EMPHASYS Femoral Stems Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, KWL, KWL, KWY, MEH Dated: September 27, 2023 Received: September 28, 2023

Dear Sarah Matamisa:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}------------------------------------------------

Sincerely,

# Limin Sun -S

Limin Sun, Ph.D. Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

Submission Number (if known)

K233233

Device Name

EMPHASYS Femoral Stems

#### Indications for Use (Describe)

EMPHASYS Femoral Stems are intended for use in total and partial hip arthroplasty. The stems are intended only for uncemented use.

Total hip arthroplasty is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.

Partial hip arthroplasty (hip hemiarthroplasty) is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of a satisfactory natural acetabulum and sufficient femoral bone to seat and support the femoral stem.

EMPHASYS Femoral Stems are intended for single use only.

# INDICATIONS

Total hip replacement is indicated in the following conditions:

1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia.

- 2. Avascular necrosis of the femoral head.
- 3. Acute traumatic fracture of the femoral head or neck.
- 4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis,
- hemiarthroplasty, surface replacement arthroplasty, or total hip replacement.
- 5. Certain cases of ankylosis.

Partial hip replacement is indicated in the following conditions:

1. Acute fracture of the femoral head or neck that cannot be appropriately reduced and treated with internal fixation.

2. Fracture dislocation of the hip that cannot be appropriately reduced and treated with internal fixation.

- 3. Avascular necrosis of the femoral head.
- 4. Non-union of femoral neck fractures.
- 5. Certain high subcapital and femoral neck fractures in the elderly.

6. Degenerative arthritis involving only the femoral head in which the acetabulum does not require replacement.

7. Pathology involving only the femoral head/neck and/or proximal femur that can be adequately treated by hip hemiarthroplasty.

## The EMPHASYS Femoral Stems are indicated for cementless use only.

Type of Use (Select one or both, as applicable)

> Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

{4}------------------------------------------------

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{5}------------------------------------------------

# 510(k) SUMMARY

(As required by 21 CFR 807.92 and 21 CFR 807.93)

| Submitter Information | |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Name | DePuy Ireland UC |
| Address | Loughbeg, Ringaskiddy<br>Co. Cork, IRELAND |
| Establishment Registration<br>Number | 3015516266 |
| Name of contact person | Sarah Matamisa |
| e-mail address | [e-mail] and [e-mail] |
| Alternative contact person | Elaine Pears |
| e-mail address | [e-mail] |
| Work mobile | [phone] |
| Date prepared | 11 October 2023 |
| Name of device | |
| Trade or proprietary name | EMPHASYS Femoral Stem |
| Common or usual name | Total or Hemi-Hip Arthroplasty Prosthesis |
| Classification name | Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented<br>Prosthesis, Hip, Semi-Constrained, Uncemented, Metal / Polymer, Non-Porous, Calcium Phosphate<br>Prosthesis, Hip, Hemi-, Femoral, Metal<br>Prosthesis, Hip, Hemi-, Femoral, Metal/Polymer, Cemented Or Uncemented |
| Class | II |
| Classification panel | 87 Orthopedics |
| Regulation | 21 CFR 888.3353<br>21 CFR 888.3360<br>21 CFR 888.3390 |
| Product Code(s) | LZO, MEH, KWL, KWY |
| Legally marketed device(s) to<br>which equivalence is claimed | Primary Predicate:<br>- EMPHASYS Femoral Stems (K211657), cleared August 5, 2021<br>Secondary Predicate:<br>- DePuy CORAIL AMT Hip Prosthesis (K203167), cleared November 19, 2020 |
| Reason for 510(k) submission | The purpose of this submission is to extend the currently approved shelf life of EMPHASYS Femoral Stems (K211657) from 5 years to 10 years. |
| Device description | The EMPHASYS Femoral Stems include HA-coated femoral stems in standard and high offsets and in collared and collarless configurations. |
| | The stems are manufactured from titanium alloy forgings per ASTM F620-20 and<br>coated with a layer of plasma-sprayed HA per ASTM F1185-14 and ISO<br>13779-6: 2015. |
| Intended use of the device | Total and Partial Hip Arthroplasty |
| Indications for use | EMPHASYS Femoral Stems are intended for use in total and partial hip arthroplasty.<br>The stems are intended only for uncemented use.<br><br>Total hip arthroplasty is intended to provide increased patient mobility and reduce pain<br>by replacing the damaged hip joint articulation in patients where there is evidence of<br>sufficient sound bone to seat and support the components.<br><br>Partial hip arthroplasty (hip hemiarthroplasty) is intended to provide increased patient<br>mobility and reduce pain by replacing the damaged hip joint articulation in patients<br>where there is evidence of a satisfactory natural acetabulum and sufficient femoral<br>bone to seat and support the femoral stem.<br><br>EMPHASYS Femoral Stems are intended for single use only.<br><br>Total hip replacement is indicated in the following conditions:<br>1. A severely painful and/or disabled joint from osteoarthritis, traumatic<br>arthritis, rheumatoid arthritis, or congenital hip dysplasia.<br>2. Avascular necrosis of the femoral head.<br>3. Acute traumatic fracture of the femoral head or neck.<br>4. Failed previous hip surgery including joint reconstruction, internal fixation,<br>arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip<br>replacement.<br>5. Certain cases of ankylosis.<br><br>Partial hip replacement is indicated in the following conditions:<br>1. Acute fracture of the femoral head or neck that cannot be appropriately<br>reduced and treated with internal fixation.<br>2. Fracture dislocation of the hip that cannot be appropriately reduced and<br>treated with internal fixation.<br>3. Avascular necrosis of the femoral head.<br>4. Non-union of femoral neck fractures.<br>5. Certain high subcapital and femoral neck fractures in the elderly.<br>6. Degenerative arthritis involving only the femoral head in which the<br>acetabulum does not require replacement.<br>7. Pathology involving only the femoral head/neck and/or proximal femur that<br>can be adequately treated by hip hemiarthroplasty. |
| | The EMPHASYS Femoral Stems are indicated for cementless use only. |

{6}------------------------------------------------

## K233233 Page 2 of 4

{7}------------------------------------------------

| SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO THE<br>PREDICATE DEVICE | | | |
|------------------------------------------------------------------------------------------------|---------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|
| Characteristics | Subject Device:<br>EMPHASYS Femoral Stems | Predicate Device:<br>EMPHASYS Femoral Stems<br>(K211657) | Predicate Device:<br>DePuy CORAIL AMT Prosthesis<br>(K203167) |
| Intended Use | Total and Hemi-Hip Arthroplasty | Total and Hemi-Hip Arthroplasty | Total and Hemi-Hip Arthroplasty |
| Material | Titanium Alloy (Ti6Al4V) with<br>HA coating | Titanium Alloy (Ti6Al4V) with<br>HA coating | Titanium Alloy (Ti6Al4V) HA<br>coating |
| Fixation | Uncemented | Uncemented | Uncemented |
| Sterile Method | Gamma | Gamma | Gamma |
| Packaging | Nylon inner and outer pouch | Nylon inner and outer pouch | Nylon Inner Pouch and<br>outer PETG blister<br>with Tyvek peel lid |
| Shelf life | 10 Years | 5 Years | 10 Years |

{8}------------------------------------------------

## PERFORMANCE DATA

### SUMMARY OF NON-CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE

The subject HA coated EMPHASYS Femoral Stems are manufactured to the same production specifications as the predicate devices (K211657 and K203167). As the subject devices have been validated to be manufactured to the same specifications and utilize the same materials, the shelf life extension will not impact the fit, form or function of these components. Therefore, the nonclinical tests reviewed as part of K211657 and K203167 remain current.

Packaging shelf-life validation has been carried out to confirm a shelf-life of 10 years.

HA coating properties on aged products were tested as per ISO-13779-3 (Crystallinity, Foreign Phases and CaP ratio), ASTM F1854 (Thickness) and ASTM E2109 (Porosity) to confirm a shelf-life of 10 years.

# SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICAL INFORMATION

No clinical tests were conducted to demonstrate substantial equivalence.

# CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA

The subject device EMPHASYS Femoral Stems is equivalent to the predicates EMPHASYS Femoral Stems (K211657) and DePuy CORAIL AMT Prosthesis (K203167). There have been no modifications made to the intended use, design, biocompatibility, materials, sterilization or packaging of the existing EMPHASYS Femoral Stems.